3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Neoplasms
3
Breast Neoplasms
3
Sarcoma
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Thymus Neoplasms
1
Sex Cord-Gonadal Stromal Tumors
1
Sarcoma, Synovial
1
Prostatic Neoplasms
1
Peritoneal Neoplasms
1
Neoplasms, Germ Cell and Embryonal
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mesothelioma
1
Meningioma
1
Lymphoma, Large B-Cell, Diffuse
1
Liposarcoma
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Glioma
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Fatigue
1
Dermatofibrosarcoma
1
Cardiovascular Diseases
1
Carcinoma, Squamous Cell
1
Brain Neoplasms
1
Interventions
fludarabine
19
Whole-Body Irradiation
18
Cyclophosphamide
17
fludarabine phosphate
16
ruxolitinib
15
Mycophenolic Acid
14
Specimen Handling
13
Tacrolimus
11
Azacitidine
11
Biopsy
10
Peripheral Blood Stem Cell Transplantation
9
Melphalan
9
Cytarabine
9
venetoclax
8
Sirolimus
8
Busulfan
8
Stem Cell Transplantation
6
Injections
6
Granulocyte Colony-Stimulating Factor
6
Daunorubicin
5
Cyclosporine
5
CPX-351
5
luspatercept
4
ivosidenib
4
itacitinib
4
fedratinib
4
decitabine and cedazuridine drug combination
4
Thiotepa
4
Liposomes
4
Cyclosporins
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myeloproliferative Disorders
×
Quality of Life
×
1 year
×
Clear all
NCT07387354
2026-03-16
MDS
Thomas Jefferson University
Phase 1/2
Not yet recruiting
25 enrolled